Info & Links
Stage IV Metastatic Breast Cancer (invasive lobular carcinoma)
PR - weakly Positive
Vicky's Medical Team:
We learned early on that the second most important element to Vicky's well being and success was the medical team that cared for her. We know that extraordinary people have come into her life to put the medical technology to work through their respective expertise and discipline. Of course, the most important element for Vicky's well being is her faith in God. And, we know that God has led us to find these talented professionals.
Dr. Stephens, (Onco) Evansville http://www.ohaev.com/Team/Physicians
Dr. Storniolo, (Onco) Indianapolis http://iuhealth.org
Dr Ting, Indianapolis (ENT) http://medicine.iu.edu/oto/about/faculty/ting/
Dr. Wesley Thompson (GP) Fairfield http://www.fairfieldmemorial.org/medical-staff
Dr. Pat Molt (Surgeon) Fairfield http://www.fairfieldmemorial.org/medical-staff
Susan G. Komen Breast Cancer Foundation www.komen.org
National Breast Cancer Foundation http://www.nationalbreastcancer.org
National Cancer Institute http://www.nci.nih.gov
American Cancer Society http://www.cancer.org
Breast Cancer.org http://www.breastcancer.org
Mayo Clinic http://www.mayoclinic.com/
People Living with Cancer.org http://www.plwc.org
About.com Cancer Info http://cancer.about.com/
European Site http://www.cancerbacup.org.uk/Home
Good link to information about lobular carcinoma:
CA 27.29 Marker
A tumor marker is a substance shed by a tumor into the bloodstream where it can be detected with a blood test to differentiate cancerous from normal tissue. CA 27.29 (i.e., Cancer Antigen 27.29) is a tumor marker for breast cancer; more specifically, it is a mucinous glycoprotein antigen made of carbohydrates (a chemical that resembles a type of sugar) and is the product of the MUC-1 gene, which is present in breast cancer cells. CA 27.29 is shed into the bloodstream in high levels when breast cancer metastasizes (spreads). As breast cancer metastasizes, the level of CA 27.29 antigen in the blood rises.
The CA 27.29 test, also known as Truquant(R) BR(TM) Radioimmunoassay (RIA), has been approved by the U.S. Food and Drug Administration (FDA) for the detection of breast cancer recurrence in patients initially diagnosed as Stage II or III. The test works by detecting the CA 27.29 antigen. Truquant BR RIA is manufactured and marketed by Biomira Diagnostics Inc., and additional information may be obtained by calling Biomira at 1-800-556-1275.
The CA 27.29 test is most useful when it is used regularly to monitor the course of disease and response to treatment; a decrease in CA 27.29 indicates a good response to treatment while an increase indicates resistance to treatment and progression of the cancer. An increase in CA 27.29 above the upper limit of normal in patients with no clinical evidence of disease has been shown to be an early indicator of recurrence. In one study, elevated CA 27.29 levels provided a positive predictive value of 83.3% for recurrent disease an average of 5.3 months before other tests or symptoms. Since the CA 27.29 test has not been shown to be able to detect CA 27.29 in all cases and has detected it falsely in others, the test is used in conjunction with other methods for monitoring breast cancer recurrence. Nevertheless, the ability of the CA 27.29 test to predict breast cancer recurrence earlier than other methods in most patients shows promise because it allows for the opportunity to treat the cancer before it has spread too much, and treatment is more effective in these early stages.
MRI and Lobular Diagnosis
|British Journal of Surgery
Volume 89 Issue 10 Page 1296 - October 2002
|Role of magnetic resonance imaging in the diagnosis and single-stage surgical resection of invasive lobular carcinoma of the breast|
|K. Munot, B. Dall*,
R. Achuthan, G. Parkin*,
and K. Horgan
Background: Conventional imaging with mammography and ultrasonography has a low sensitivity for diagnosis and a tendency to underestimate the extent of invasive lobular carcinoma (ILC) of the breast. The aim was to determine whether magnetic resonance imaging (MRI) had any advantages for the characterization of ILC.
Methods: Twenty patients with histologically proven ILC underwent preoperative imaging with MRI. MRI was performed to aid detection of malignancy in six patients with a clinically suspicious presentation but normal or indeterminate imaging on mammography and ultrasonography. In 14 patients MRI was performed to determine tumour extent.
Results: MRI accurately identified malignancy in five of six patients with normal or indeterminate conventional imaging. In seven of 14 patients in whom MRI was performed to determine tumour extent, it provided significant additional information. These included four patients in whom conventional imaging grossly underestimated tumour size, two patients in whom MRI identified an unsuspected contralateral breast tumour and one patient in whom MRI predicted tumour invasion of the pectoral muscle. The correlation between tumour size on histological examination was better with MRI (r = 0·967) than with mammography (r = 0·663) and ultrasonography (r = 0·673).